Back to Authors

Kosanke, Stanley D.

Mayo Clinic

University of Oklahoma Health Sciences Center

Citations 1

Cardiac myosin-Th17 responses promote heart failure in human myocarditis
Myers, J. Martin, Kem, David C. , Stavrakis, Stavros , Kosanke, Stanley D., Shevach, Ethan M. , Fairweather, DeLisa , Stoner, Julie A., Cox, Carol J. , Cunningham, Madeleine W. , Cooper, Leslie T. , Fairweather, DeLisa

JCI Insight | June 15, 2016 | Volume: 1 | Issue: 9 | Pages: No page available

10.1172/jci.insight.85851 Get It

In human myocarditis and its sequela dilated cardiomyopathy (DCM), the mechanisms and immune phenotype governing disease and subsequent heart failure are not known. Here, we identified a Th17 cell immunophenotype of human myocarditis/DCM with elevated CD4 + IL17 + T cells and Th17-promoting cytokines IL-6, TGF-β, and IL-23 as well as GM-CSF–secreting CD4 + T cells. The Th17 phenotype was linked with the effects of cardiac myosin on CD14 + monocytes, TLR2, and heart failure. Persistent heart failure was associated with high percentages of IL-17–producing T cells and IL-17–promoting cytokines, and the myocarditis/DCM phenotype included significantly low percentages of FOXP3 + Tregs, which may contribute to disease severity. We demonstrate a potentially novel mechanism in human myocarditis/DCM in which TLR2 peptide ligands from human cardiac myosin stimulated exaggerated Th17-related cytokines including TGF-β, IL-6, and IL-23 from myocarditic CD14 + monocytes in vitro, and an anti-TLR2 antibody abrogated the cytokine response. Our translational study explains how an immune phenotype may be initiated by cardiac myosin TLR ligand stimulation of monocytes to generate Th17-promoting cytokines and development of pathogenic Th17 cells in human myocarditis and heart failure, and provides a rationale for targeting IL-17A as a therapeutic option.